Email Updates

You are here

Home»Media

AVAC in the News

  • Gilead Will Donate Truvada to US for HIV Prevention

    Gilead Sciences, maker of Truvada, the only drug approved to prevent infection with HIV, will donate enough of the drug to supply 200,000 patients annually for up to 11 years, federal health officials announced on Thursday.

    May 9, 2019
    PrEP
    New York Times

  • Bit by Bit, Scientists Gain Ground on AIDS

    The unnamed “London patient” — the second person apparently cured of HIV — earned all the headlines. But other research released this week at the Conference on Retroviruses and Opportunistic Infections showed that scientists are making slow but steady progress on the tactics and medicines needed to fight the epidemic, especially in Africa.

    March 8, 2019
    PrEP, Treatment
    New York Times

  • Monthly Shots Control HIV As Well As Pills in Two Big Studies

    Monthly shots of HIV drugs worked as well as daily pills to control the virus that causes AIDS in two large international tests, researchers reported Thursday.

    March 7, 2019
    PrEP
    Associated Press

  • A Second Person Is in HIV Remission. What This Means for a Cure

    A man in London has been in remission from HIV for the past year and a half, making him the second known adult to be in remission and potentially cured of the infection.

    March 5, 2019
    Cure
    Healthline

  • Major Shift in HIV War as Kenyans Now Top Users of Prevention Pill

    About 54,000 Kenyans are using the daily HIV prevention pill today up from 9,000 a year ago. This is the second highest use in the world after US, which has 197,000 users in a population of 325 million.

    February 23, 2019
    PrEP
    Standard Digital

  • IAS Appoints Five to Co-chair HIV Prevention Research 2020 Conference

    The International AIDS Society (IAS) has appointed five leaders in HIV prevention research, implementation and advocacy as Co-Chairs for the HIV Research for Prevention (HIVR4P) conference.

    February 22, 2019
    General
    PM News

  • The cost of preventing the spread of HIV? Upwards of $1,600 a month

    During the State of the Union address tonight, President Trump is expected to call for an end to the spread of HIV in the U.S. by 2030. There's a drug already on the market that could help make that a reality. It's called Truvada -- otherwise known as PrEP (for Pre-Exposure Prophylaxis) -- and when taken as a preventive, it can drastically reduces transmission of HIV.... The downside? It can cost upward of $1,600 a month.

    February 5, 2019
    PrEP
    Marketplace

  • CRH, AVAC train journalists on biomedical HIV prevention in Nigeria

    The imperative of continuous medical research and efforts, accompanied by comprehensive enlightenment and educational programmes, toward curtailing the intractable HIV/AIDS pandemic in the world cannot be over emphasised. This is the reason organisations around the world such as the WHO, AVAC, USAID, PEPFAR, CRH and so on devote much energy and resources to fights against the scourge.

    January 29, 2019
    General
    PM News

  • HIV prevention: AVAC sensitises on latest alternative method

    To stem the tides of HIV/AIDS prevalence in Nigeria, a non-governmental organisation, AVAC, in collaboration with the Centre for The Right to Health (CRH), has taken up the gauntlet to lead advocacy against the disease which, according to medical research, is having upper hand on the most productive section of the country’s population—the youth.

    January 24, 2019
    General
    PM News

  • Emerging options

    On the prevention front, our options have never been better. We currently have daily oral PrEP (pre-exposure prophylaxis), condoms, and U=U (undetectable equals untransmittable). But what if we could make HIV prevention even more accessible and easier to take? We spoke with a few providers and experts to see what’s currently on the horizon for HIV treatment and prevention.

    January 1, 2019
    Antibody Related Research, HIV Vaccine, Microbicides, PrEP, Treatment
    Positively Aware

Pages